| Symbol | IMNN |
|---|---|
| Name | IMUNON, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 997 LENOX DRIVE,SUITE 100, LAWRENCEVILLE, New Jersey, 08648, United States |
| Telephone | +1 -609 896-9100 |
| Fax | — |
| — | |
| Website | https://www.imunon.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0000749647 |
| Description | Imunon Inc is developing new medicines that harness the building blocks of life to work in harmony with the bodys immune system. It is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. Additional info from NASDAQ: |
(90% Positive) IMUNON, INC. (IMNN) Announces Enrollment Update for generated Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment
Read moreIMUNON Reports Strong Enrollment Momentum in Phase 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian Cancer
Read moreIMUNON to Present IMNN-001 Data at Inaugural AACR Conference on Drug Discovery and Development
Read moreDirector Tardugno Michael H 🟢 acquired 4.6K shares of Imunon, Inc. (IMNN) at $1.83 Transaction Date: Jul 17, 2026 | Filing ID: 023949
Read moreEylward Susan 🟡 adjusted position in 0 shares of Imunon, Inc. (IMNN) at $1.83 Transaction Date: Jul 17, 2026 | Filing ID: 023948
Read moreFaller Douglas Vincent 🟢 acquired 3.1K shares of Imunon, Inc. (IMNN) at $1.83 Transaction Date: Jul 17, 2026 | Filing ID: 023947
Read moreDirector Lindborg Stacy 🟢 acquired 4.9K shares of Imunon, Inc. (IMNN) at $1.83 Transaction Date: Jul 17, 2026 | Filing ID: 023946
Read moreIMUNON Reports Positive Phase 2 MRD Clinical Data for IMNN-001, Demonstrating the Successful Overcoming of Historical IL-12 Safety Barriers in Frontline Ovarian Cancer
Read moreDirector Tardugno Michael H 🟢 acquired 4.4K shares of Imunon, Inc. (IMNN) at $1.91 Transaction Date: Jul 02, 2026 | Filing ID: 022948
Read more